title: Ledipasvir and sofosbuvir for treatment of post- renal transplant hepatitis C infection: A case report with review of literature.
abstract: Liver disease due to hepatitis C infection in renal transplant recipients is difficult to treat and often associated with reduced patient survival. A 43-year-old male, a renal allograft recipient, presented at 6 years follow-up with significant weight loss over 3 months. He was detected to have new onset diabetes mellitus together with hepatitis C virus (HCV) infection (genotype 1). His HCV load remained high despite the change of immuno-suppression from tacrolimus to cyclosporine. A decision to treat with a new anti-viral combination of ledipasvir and sofosbuvir for 12 weeks was taken. Within 3 weeks, his raised serum transaminases levels normalized and viral load became undetectable. At the end of 16 weeks, he continues to do well with normal renal function, has sustained remission from hepatitis C infection and resolution of diabetes.
authors.affiliation: Department of Nephrology, Medwin Hospital, Hyderabad, Telangana, India.
authors.forename: R
authors.initials: R
authors.lastname: Jha
authors.affiliation: Department of Nephrology, Medwin Hospital, Hyderabad, Telangana, India.
authors.forename: R
authors.initials: R
authors.lastname: Fatima
authors.affiliation: Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, Telangana, India.
authors.forename: S
authors.initials: S
authors.lastname: Lakhtakia
authors.affiliation: Department of Medicine, Mediciti Medical College, Hyderabad, Telangana, India.
authors.forename: A
authors.initials: A
authors.lastname: Jha
authors.affiliation: Department of Nephrology, Medwin Hospital, Hyderabad, Telangana, India.
authors.forename: P
authors.initials: P
authors.lastname: Srikant
authors.affiliation: Department of Nephrology, Medwin Hospital, Hyderabad, Telangana, India.
authors.forename: G
authors.initials: G
authors.lastname: Narayan
keywords: Hepatitis C infection; ledipasvir; renal transplant; sofosbuvir